This content is restricted to registered user. If you are an existing user, please log in. New users may register for free.
New Merger between Pfizer and Anacor Set to Leverage Companies in Atopic Dermatitis Space, says GlobalData Analyst
An upcoming merger agreement between Pfizer and Anacor, worth around $5.2 billion, could boost the marketing power of Anacor’s lead pipeline candidate, crisaborole, and pave the way for Pfizer to launch its